Abstract:Objective: To detect the serum epithelial growth factor receptor (EGFR) gene mutation status in patients with lung cancer via second-generation sequencing and to analyze its correlations with the clinical features of patients and its therapeutic effects. Methods: A total of 110 patients with non-small cell lung cancer (NSCLC) treated in our hospital were recruited as subjects of our study. The distribution of the EGFR gene mutation in patients was detected via second-generation sequencing and then patients were divided into mutant-type EGFR group (n=37) and wild-type EGFR group (n=73). The clinical features and therapeutic effects were compared between the two groups of patients. Results: A total of 5 kinds of EGFR gene mutation [19del (45.95%), L858R (43.24%), L861Q (5.41%), S768I (2.70%), and G719X (2.70%)] were detected via second-generation sequencing. In the mutant-type EGFR group, the proportions of female patients, patients with adenocarcinoma, and those with no history of smoking were high, and the differences were statistically significant (P<0.05). Moreover, there were statistically significant differences in gender, type of cancer, tumor-node-metastasis (TNM) staging, and smoking history between the mutant-type EGFR group and the wild-type EGFR group (P<0.05). Results of a multivariate logistic regression analysis showed that the EGFR gene mutation status was significantly associated with the type of cancer, gender, TNM staging, and smoking history of patients with NSCLC (P<0.05). The clinical effective rate of patients in the mutant-type EGFR group was significantly higher than that in the wild-type EGFR group (54.05% vs. 19.18%) while progression-free survival (PFS) was significantly longer than that in the wild-type EGFR group [(9.75±1.64) months vs. (5.51±0.40) months] (P<0.05). The expression level of carcinoembryonic antigen (CEA) in patients in the mutant-type EGFR group was apparently higher than that in the wild-type EGFR group, but the levels of carbohydrate antigen 125 (CA125), CY21-1 and squamous cell carcinoma-related antigen (SCC-Ag) were apparently lower than those in the wild-type EGFR group. There were statistically significant differences in the expression levels of serum tumor markers between the two groups (P<0.05). Conclusion: EGFR mutation status is closely related to the clinical features of NSCLC patients, such as gender, type of cancer, tumor staging, smoking history, and clinical effect. The second-generation sequencing is an important detection method to identify EGFR gene mutation status, which provides an applicable scaffold for the clinical treatment of patients.

Analysis of Clinical Significance on EGFR Detection in Patients with Non-Small Cell Lung Cancer

[Clinicopathological Features Associated with EGFR Gene Mutation in Non-Small Cell Lung Cancer Patients].

Clinical significance of multi-sample next-generation sequencing for detection of gene mutations in non-small cell lung cancer

Clinical value of epidermal growth factor receptor mutation testing in peripheral blood of patients with non-small cell lung cancer

Analysis of EGFR Mutation in Chinese Non-Small Cell Lung Cancer Patients

[Detection of Epidermal Growth Factor Receptor Mutations in Non-Small-cell Lung Carcinoma by Direct Sequencing and Correlations with Clinicopathological Characteristics and Sample Types].

EGFR Gene Mutation and Methodological Evaluation in 399 Patients with Non-small Cell Lung Cancer

Serum EGFR gene mutation status via second-generation sequencing and clinical features of patients with advanced lung cancer

Distinguishing EGFR mutant subtypes in stage IA non-small cell lung cancer using the presence status of ground glass opacity and final histologic classification: a systematic review and meta-analysis

The Prevalence of EGFR Mutation in Patients with Non-Small Cell Lung Cancer: a Systematic Review and Meta-Analysis

Detection And Clinical Significance Of Intratumoral Egfr Mutational Heterogeneity In Chinese Patients With Advanced Non-Small Cell Lung Cancer

Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China

Predicting Significance of EGFR Mutation Existing in Tissues and Plasma Concuurrently or Alone to EGFR–tyrosine Kinase Inhibitors (Egfr-Tkis) for Advanced Non-Small Cell Lung Cancer.

Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation

Intratumoral Heterogeneity of EGFR Mutation and Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer.

Detection of EGFR gene mutations with mutation-speciifc immunohistochemistry in non-small cell lung cancer

The prognostic impact of epidermal growth factor receptor mutation in clinical stage I lung adenocarcinoma

Relationship of the curative effects of gefitinib on non-small cell lung carcinoma to gender and to epithelial growth factor receptor status

Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of 18F-FDG PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag

EGFR Mutations in Correlation with the Tumor Markers in NSCLC Patients

Influence of Chemotherapy on EGFR Mutation Status among Patients with Non-Small-cell Lung Cancer.